Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jul;72(7):2217-2231.
doi: 10.1007/s00262-023-03384-9. Epub 2023 Mar 3.

Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach

Affiliations
Multicenter Study

Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach

Andrea Botticelli et al. Cancer Immunol Immunother. 2023 Jul.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have particular, immune-related adverse events (irAEs), as a consequence of interfering with self-tolerance mechanisms. The incidence of irAEs varies depending on ICI class, administered dose and treatment schedule. The aim of this study was to define a baseline (T0) immune profile (IP) predictive of irAE development.

Methods: A prospective, multicenter study evaluating the immune profile (IP) of 79 patients with advanced cancer and treated with anti-programmed cell death protein 1 (anti-PD-1) drugs as a first- or second-line setting was performed. The results were then correlated with irAEs onset. The IP was studied by means of multiplex assay, evaluating circulating concentration of 12 cytokines, 5 chemokines, 13 soluble immune checkpoints and 3 adhesion molecules. Indoleamine 2, 3-dioxygenase (IDO) activity was measured through a modified liquid chromatography-tandem mass spectrometry using the high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method. A connectivity heatmap was obtained by calculating Spearman correlation coefficients. Two different networks of connectivity were constructed, based on the toxicity profile.

Results: Toxicity was predominantly of low/moderate grade. High-grade irAEs were relatively rare, while cumulative toxicity was high (35%). Positive and statistically significant correlations between the cumulative toxicity and IP10 and IL8, sLAG3, sPD-L2, sHVEM, sCD137, sCD27 and sICAM-1 serum concentration were found. Moreover, patients who experienced irAEs had a markedly different connectivity pattern, characterized by disruption of most of the paired connections between cytokines, chemokines and connections of sCD137, sCD27 and sCD28, while sPDL-2 pair-wise connectivity values seemed to be intensified. Network connectivity analysis identified a total of 187 statistically significant interactions in patients without toxicity and a total of 126 statistically significant interactions in patients with toxicity. Ninety-eight interactions were common to both networks, while 29 were specifically observed in patients who experienced toxicity.

Conclusions: A particular, common pattern of immune dysregulation was defined in patients developing irAEs. This immune serological profile, if confirmed in a larger patient population, could lead to the design of a personalized therapeutic strategy in order to prevent, monitor and treat irAEs at an early stage.

Keywords: Immunotherapy; Network; Solid tumors; Soluble profile; Toxicity.

PubMed Disclaimer

Conflict of interest statement

PAOLO MARCHETTI (PM) has/had a consultant/advisory role for BMS, Roche-Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte. The other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Connectivity heatmap between the soluble molecule expression profiles and the toxicity values. Statistically significant Spearman correlations (adjusted p value ≤ 0.05) are reported. In the plot, circles are scaled and colored according to the correlation values, increasing from red (negative correlation) to blue (positive correlation). Soluble molecules are grouped and ordered according to the functional group reported in the legend
Fig. 2
Fig. 2
Boxplot of biomarker expression level (logarithmic scale) in 52 patients with toxicity equal to 0 (violet box) and 27 patients with toxicity equal to 1 (water blue box). Adjusted p values (p) were obtained by performing the Mann–Whitney test for unpaired samples. Only biomarkers showing a statistically significant difference between the two groups are reported. (* adjusted p value ≤ 0.05)
Fig. 3
Fig. 3
Connectivity heatmap between soluble molecules in patients without toxicity (A) and with toxicity (B). Statistically significant Spearman correlations (adjusted p value ≤ 0.05) are reported. In the plot, circles are scaled and colored according to the correlation values, increasing from red (negative correlation) to blue (positive correlation). Soluble molecules are grouped and ordered according to the functional groups reported in the legend
Fig. 4
Fig. 4
Connectivity network between soluble molecules in patients without toxicity (A) and in patients with toxicity (B). In each network, nodes represent soluble molecules and a link occurs between two nodes if the absolute value of Spearman correlation between their expression levels is statistically significant (adjusted p value ≤ 0.05) and greater than a selected threshold (i.e., the 85th percentile of the overall distribution corresponding to 0.6). Nodes are colored according to the functional groups reported in the legend and their size scales with the network degree (i.e., number of connections of each node), while edge color indicates positive (blue) or negative (red) correlation values
Fig. 5
Fig. 5
Connectivity network of soluble molecules connections shared between patients with and without toxicity (A), specifically present in patients without toxicity (B) and specifically present in patients with toxicity (C). Networks that are specific for patients without (B) or with toxicity (C) are obtained by keeping only the connections that are not shared between the two groups. In each network, nodes represent soluble molecules and a link occurs between two nodes if the absolute value of Spearman correlation between their expression levels is statistically significant (adjusted p value p ≤ 0.05) and greater than a selected threshold (i.e., the 85th percentile of the overall distribution corresponding to 0.6). Nodes are colored according to the functional groups reported in the legend and their size scales with the network degree (i.e., number of connections of each node). In the specific networks (B-C), edge colors indicate positive (blue) or negative (red) correlation values

Similar articles

Cited by

References

    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR. KEYNOTE-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;10375(19):1823–1833. doi: 10.1056/NEJMoa1606774. - DOI - PubMed
    1. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Jr, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7. - DOI - PubMed
    1. Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, Glover MS, Simien R, Diab A, Hwu P, Carter BW, Patel SP. Nivolumab and Ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39(6):599–607. doi: 10.1200/JCO.20.00605. - DOI - PMC - PubMed
    1. Kaštelan S, Antunica AG, Oresković LB, Pelčić G, Kasun E, Hat K. Immunotherapy for uveal melanoma-current knowledge and perspectives. Curr Med Chem. 2020;27(8):1350–1366. doi: 10.2174/0929867326666190704141444. - DOI - PubMed
    1. Masaoutis C, Kokkali S, Theocharis S. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment. Expert Opin Investig Drugs. 2021;30(5):555–569. doi: 10.1080/13543784.2021.1898587. - DOI - PubMed

Publication types

Substances